Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097369 · ClinicalTrials.gov registry record
Elitek (Rasburicase) Immuno-Monitoring Study
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01097369: Clinical Trial study, sponsored by Sanofi.
NCT01097369 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01097369 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-02 |
Why NCT01097369 stopped before completion
NCT01097369 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01097369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01097369 about?
NCT01097369 is a clinical study titled "Elitek (Rasburicase) Immuno-Monitoring Study". Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hyper...
What is the current status of trial NCT01097369?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2010-02. Estimated completion is 2010-02.
Who is sponsoring clinical trial NCT01097369?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia